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ABSTRACT
Introduction: Cervical cancer affects half a million women worldwide annually. Given the association 
between high-risk human papillomavirus (hrHPV) infection and carcinogenesis, hrHPV DNA testing 
became an essential diagnostic tool. However, hrHPV alone does not cause the disease, and, most 
importantly, many cervical lesions regress to normal in a year because of the host immune system. 
Hence, the low specificity of hrHPV DNA tests and their inability to predict the outcome of infections 
have triggered a further search for biomarkers.
Areas covered: We evaluated the latest viral and cellular biomarkers validated for clinical use as 
primary screening or triage for cervical cancer and assessed their promise for prevention as well as 
potential use in the future. The literature search focused on effective biomarkers for different stages of 
the disease, aiming to determine their significance in predicting the outcome of hrHPV infections.
Expert opinion: Biomarkers such as p16/Ki-67, hrHPV genotyping, hrHPV transcriptional status, and 
methylation patterns have demonstrated promising results. Their eventual implementation in the 
screening programs may support the prompt diagnosis of hrHPV infection and its progression to 
cancer. These biomarkers will help in making clinical management decisions on time, thus, saving the 
lives of hrHPV-infected women, particularly in developing countries.
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1. Introduction
Cervical cancer is the third most frequent cancer in women 
worldwide after breast cancer or colon cancer. Even though 
the application of screening programs has lowered the inci-
dence and mortality, cervical cancer remains one of the most 
malignant diseases among women. Over 62% of the deaths 
related to cervical cancer occur in low and middle-income 
countries, where access to screening programs and treatment 
is limited [1].
Human papillomavirus (HPV) is an ancient, non-enveloped 
double-stranded DNA virus from the family Papillomaviridae 
that causes the most common sexually transmitted infection 
with more than 14 million new infections annually. Over 80% 
of women become infected at some stage in their life. HPV 
family is divided into five genera based on their DNA 
sequences, life-cycle characteristics and disease associations. 
The Beta and Gamma genera are associated with asympto-
matic infections causing cutaneous lesions. The genus 
Alphapapillomaviruses, causing mucosal and cutaneous infec-
tions, has an oncogenic role in the progression of HPV infec-
tion to cervical cancer. Within this genus, genotypes 16 and 18 
are the major carcinogenic types, causing approximately 70% 
of all cervical cancers. Additionally, the World Health 
Organization (WHO) also includes genotypes 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66, 68 and 73 to the high-risk HPV 
(hrHPV) grouThe remaining genotypes of the alpha genus, 
classified as low risk, are rarely associated with neoplasia 
causing mainly asymptomatic infections or benign papillomas, 
which are resolved by the host immune system [2–4]. 
Persistent infection is the etiological agent for the majority 
of all cervical cancers due to the ability of hrHPV to persist and 
drive cell proliferation in the cervical transformation zone [2]. 
Squamous cell carcinoma (SCC) is the most common type of 
cancer caused by hrHPV infections, while in rare cases, the 
infection progress to adenocarcinomas (ADC). The latter com-
prises approximately 10–20% of all cervical cancers, with 
60–100% of them being related to hrHPV [5].
The infectious HPV life cycle is linked to the differentiation 
process of the host squamous stratified cervical epithelium 
Figure 1A. The life cycle begins with the viral entrance through 
a microwound in the cervical epithelium. HPV capsid proteins, 
L1 and L2, get attached to the basement membrane, and after 
two to four hours, get internalized, allowing the infection of 
basal epithelial cells. Viral genome is established as an extra-
chromosomal circular episome with access to the cellular 
transcription and replication machinery. Viral DNA goes 
through a restricted number of replication cycles maintaining 
a latent infection with a low episome copy number per 
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nucleus (around 10–200 copies). Infected basal cells undergo 
natural keratinocyte terminal differentiation in the transforma-
tion zone, carrying the viral genome with them. During this 
process, the viral genome is going to be expressed gradually. 
E1 and E2 genes are expressed to maintain the viral DNA as an 
episome and to facilitate the correct segregation of genomes 
during cell division [6]. These proteins also allow the initial 
amplification of the virus and viral genome partitioning during 
basal cell division. In uninfected epitheliums, basal cells end 
the cell cycle and migrate to the suprabasal cell layer to 
undergo terminal differentiation. Upon HPV infection, this 
process is retarded because the expression of the oncopro-
teins E6 and E7 at low levels causes cell proliferation. E7 
interferes with pRb, preventing the cell from entering 
S-phase, and E6 inhibits p53, causing inactivation of apoptosis. 
For a productive infection, HPV virions must amplify their viral 
genomes to package them into infectious particles. In the mid- 
layers, the expression of E4, with the contribution of E1, E2, 
and E5 viral proteins, facilitate viral genome amplification. The 
presence and accumulation of viral E4 proteins coincide with 
the formation of koilocytotic cells (cells with an enlarged and 
irregular nucleus) [7]. Koilocytosis could contribute to viral 
dissemination in the upper layers of the epithelia due to 
keratinocyte fragility. In the upper epithelial layer, the E4 
positive cells leave the cell cycle and express the two struc-
tural proteins, L1 and L2. These particles allow viral genome 
assembly, packaging, and releasing of new infective virions 
[6,8–11].
The expression of all HPV genes (including oncogenic E6 
and E7) at low levels has a subclinical consequence. Most of 
such transient infections will clear in non- 
immunocompromised patients within a year due to the host 
immune system [12,13]. Progression is closely related to HPV 
persistence. Persistent infections are associated with a higher 
risk of HPV DNA integration into the host genome. HPV16 has 
longer persistence than other high-risk types [14]. Although in 
high-grade lesions, HPV is frequently integrated in the host 
cell genome, not all HPV genome integrations lead to cancer 
[15]. Integration is not a normal process in the HPV life cycle as 
it is characterized by the deletion of essential viral genes for 
the synthesis of infecting virions. Therefore, it is disadvanta-
geous for the virus. Upon integration, the circular HPV 
Article highlights
● Novel viral and cellular biomarkers may improve the timely diagnosis 
of hrHPV infection and cervical lesions before they progress to 
malignancy or regress to normal.
● Viral indicators such as hrHPV genotyping, load, transcriptional status, 
and E4 protein, as well as cellular indicators such as p16/Ki-67, 
TOP2A/MCM2, chromosomal gains, and miRNAs, might be good 
predictors of hrHPV risk status.
● Collection methods based on self-sampling might increase the dis-
ease’s detection rate, and combined with biomarkers testing, may 
improve the screening programs for cervical cancer worldwide, espe-
cially in low-resource settings.
Figure 1. Life cycle of high-risk Human Papillomavirus (hrHPV) in cervical epithelia and the progression from infection to cervical cancer. 1A) First, hrHPV 
enters through a microwound to the basal membrane of the cervical epithelia, where the infected cells are maintained as a reservoir. The expression of E1 and E2 
proteins drives the initial viral amplification in the lower layers of the epithelia. When these cells divide, the expression of E6 and E7 proteins stimulates cell 
proliferation (orange cells with a light orange nucleus) to the mid-layers of the epithelia. In the mid-layers, the expression of E4 with the help of E1, E2, and E5 
facilitates higher viral DNA amplification (orange cells with an enlarged and irregular nucleus, known as koilocytotic cells). Finally, the cells leave the cell cycle (E4+) 
and express L1 and L2 proteins, allowing the packaging of the amplified virus (orange cells with a dark orange nucleus) and the subsequent release. Gene 
expression of viral proteins (right arrow), viral DNA amplification, and cell proliferation (left arrows) start from low levels (light orange) at the basal layers and go to 
high levels (dark orange) at the mid or upper layers of the cervical epithelia in hrHPV-infected women. 1B) After an hrHPV infection, the virus induces cell 
proliferation, and the infected tissue can progress to CIN. The first lesions, low-grade intraepithelial lesions (LSIL, CIN1), might regress after one year. However, they 
can also progress to high-grade intraepithelial lesions (HSIL, CIN2 – CIN3) and then to cervical cancer. CIN: cervical intraepithelial neoplasia.
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genome is linearized, disrupting the E2 gene and resulting in 
its inactivation. Its function was to repress the viral E6 and E7 
oncogenes promoter, but E2 inactivation will lead to increased 
expression and stability of transcripts encoding the E6 and E7 
proteins. These oncoproteins mediate degradation of the 
tumor suppressor genes p53 and pRb [16–19]. Thus, detecting 
the transcriptionally active HPV is valuable, as well as the 
analysis of upregulated viral genes, and the consequent cel-
lular implications that result in neoplastic changes.
Three prophylactic vaccines against HPV infection (Gardasil, 
Gardasil 9, and Cervarix) have been approved by the U.S Food 
and Drug Administration (FDA). They consist of noninfectious 
virus-like particles made up of the major HPV capsid protein 
L1. Gardasil is a quadrivalent vaccine against HPV types 6, 11, 
16, and 18, Gardasil 9 is a 9-valent vaccine costing of the same 
types that Gardasil with additional inclusion of genotypes 31, 
33, 45, 52, and 58. Cervarix is a bivalent vaccine against HPV16 
and 18. These prophylactic vaccines are administered in three 
doses to females age 9 to 26 years old in an attempt to 
prevent infection. Furthermore, HPV vaccines are not intended 
for the treatment of infections or disease, as they are not 
effective in treating pre-existing HPV infections. They were 
found to provide nearly 100% protection against cervical 
infections with HPV genotypes 16 and 18 and high efficacy 
in preventing precancerous cervical lesions caused by these 
genotypes. However, vaccinated women should continue 
being screened with Papanicolau (PAP) test because no sig-
nificate reduction has been observed for the borderline/ 
ASCUS and low-grade dyskaryosis/LSIL after vaccination 
[20–23].
Papanicolau test, which uses cytologic smears, is one of the 
most effective methods used for screening of cervical cancer 
since the 1950s. Lesions found by this technique can be 
graded in different cellular abnormality levels (PAP1, PAP2, 
PAP3a1, PAP3a2, PAP3b, PAP4, PAP5), (Supplementary 
Figure 1), in which the increased grading number positively 
correlates with the number of dysplastic cells observed in the 
smear. The Bethesda system for cervical cytology has created 
a widely used terminology, where cervical cancer precursors 
are classified as low-grade squamous intraepithelial lesions 
(LSIL) or high-grade squamous intraepithelial lesions (HSIL). 
An LSIL diagnosis is based on the identification of abnormal 
squamous cells with the size of a normal superficial or inter-
mediate cell. The diagnose of an HSIL relies on the presence of 
abnormal squamous cells smaller than those present in low- 
grade lesions. A normal PAP test (PAP1) is a negative result for 
intraepithelial lesion or malignancy (NILM). Moreover, detec-
tion of atypical squamous cells (ASC), which include cells of 
undetermined significance (ASCUS) and with a higher risk of 
being precancerous (ASCUS+), results from morphologic varia-
bility of squamous cells in different physiological and patho-
logical states [22,24].
Although squamous lesions are easily detected by cytol-
ogy, which is designed to detect cells on the surface of the 
cervix, glandular lesions are not detected by this method. 
Such lesions are visible in histological examination via 
biopsy. The epithelial alterations that constitute cervical 
intraepithelial neoplasia (CIN) have been semiquantitatively 
divided into three categories: CIN1 to CIN3 (Figure 1B and 
Supplementary Figure 1). CIN1 lesions (or low-grade CIN) are 
flat warts that retain the ability to complete the HPV life 
cycle and produce virus particles. In this case, proliferation is 
at a low level, occupying the lower third of the epithelium. 
CIN2 lesions are characterized by basaloid cells filling the 
lower one to two-thirds of the epithelium. Lastly, CIN3 
lesions hold two-thirds of the thickness of the epithelium, 
which makes it a preliminary stage of cervical cancer. Both 
CIN2 and CIN3 are considered high-grade CIN since they are 
at risk for cervical cancer development [18,19,24].
More than half of new cases of cervical cancer occur 
among women who are not attending the screening pro-
gram or in women above the screening age. This shows the 
need to find alternative ways to improve attendance in the 
screening programs. HPV self-sampling is a strategy that 
may help in increasing cervical cancer screening and define 
a global direction for many national screening programs. 
For example, in The Netherlands, women that do not wish 
to have a cervical sample taken at their general practitioner 
(GP) can request a self-sampling kit [25,26]. The application 
of this technique has demonstrated to increase the partici-
pation of hard-to-reach or ‘non-responders’ women in the 
screening programs [26,27]. The convenience, privacy, ease- 
of-use, and cost-effectiveness are valuable benefits of self- 
sampling kits. Several studies have compared the sensitivity 
of self-sampling to physician-collection samples and con-
cluded that both have similar results. Nevertheless, there 
are still barriers such as confidence in self-sampling, cul-
tural implications of sexual behavior, or trust within rela-
tionships. In addition, technical errors like incorrect 
sampling or storage can influence the sensitivity and nega-
tive predictive value of the test, leading to false-negative 
results [27–30].
The cytology test has reduced the incidence of cervical 
cancer over the last 30 years. Still, it has limited capability to 
predict the presence of abnormalities in the cervix as well as 
progression from hrHPV infections to disease. Knowing that 
cervical cancer is still a prevalent disease, it is imperative to 
predict which patients have increased risk for cervical lesions. 
This has stimulated the search for new tools for screening and 
predicting cervical cancer. As comprehension of the infection 
increased, and more tests become available with time, the 
definition of better screening methods can lead to an eventual 
remodeling of the current diagnosis flowchart. hrHPV DNA 
analysis is one of the most relevant tests applied worldwide 
[24,31]. Subsequently, the Netherlands became the first coun-
try in the world to implement this method in the national 
hrHPV population-based screening program in 2017, making 
the full transition from cytology to primary hrHPV screening 
[32]. In addition, Italy introduced HPV screening in 2014, which 
is within an ongoing national implementation along with 
other European countries such as Spain, and Finland [33,34]. 
Moreover, the performance of the HPV mRNA test as a primary 
screening was assessed within the framework of the 
Norwegian and Swedish population-based screening pro-
grams [35–37]. The results were similar to the outcome of 
initial hrHPV DNA testing but demonstrating an advantage in 
decreasing cytology assessments. Based on these results, 
a positive recommendation was given to consider hrHPV 
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mRNA analysis as a primary test for population-based screen-
ing of the disease.
In cervical cancer prevention, an ideal biomarker must 
detect the progression of hrHPV infection to disease and 
allow clinical management decisions in time. These decisions 
include further testing, treatment, referral to colposcopy, 
increased surveillance, or release to routine screening. 
Biomarkers can be implemented in a wide range of steps 
within the disease flowchart. Some of these markers seem 
promising in replacing primary screening, while others are 
more suitable for triage, or can be used alongside primary 
tests. Biomarkers can also be used to estimate the prognosis 
of cancer patients, determine the impact of novel treatments 
as well as being used to monitor treatment progression.
In general, we can categorize cervical cancer-related bio-
markers into two broad groups: viral and cellular biomarkers 
[38,39]. This review aims to summarize characterized and well- 
described biomarkers for cervical cancer in hrHPV-infected 
women and demonstrate their importance in the disease 
flowchart. Here, we evaluate their advantages and disadvan-
tages according to the analysis of recent research and litera-
ture. We also explore the application of biomarkers for specific 
stages of the disease and their combined use with self- 
collected samples.
2. The viral biomarkers
hrHPV infection itself is confirmed to be the essential etiolo-
gical agent of invasive cervical cancer development. Therefore, 
a large amount of research is focused on biomarkers directly 
linked to the HPV life cycle and natural history of HPV- 
dependent cervical carcinogenesis, such as hrHPV DNA test-
ing, genotyping, viral load, transcriptional status, viral DNA 
methylation, and expression of certain viral proteins relevant 
in the viral life cycle. In this part, we will discuss the most 
suitable viral related biomarkers Figure 2 and their potential 
use for cervical cancer risk assessment and prevention.
2.1. hrHPV DNA testing
After HPV infects host cells, viral DNA is maintained as an 
episome establishing a latent infection. A switch into 
a productive infection is associated with the assembling of 
infective virions. Persistent infection with hrHPV genotypes 
triggers the integration of viral DNA into the host genome. 
Next, the viral oncoproteins will be expressed, enhancing the 
progression of preinvasive lesions to cervical cancer. 
Therefore, a necessary condition for squamous intraepithelial 
lesions (SILs) and cervical cancer is a persistent infection of 
high-risk Human Papillomavirus [40–42].
Due to this causal relationship, hrHPV DNA testing is nowa-
days one of the most wide-ranging biomarkers for primary 
screening of cervical cancer. This assay is considered a gold 
standard for the diagnosis of early HPV infection, allowing the 
detection of the 14 most carcinogenic hrHPV genotypes: 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 [2,3,10]. The 
method has high sensitivity and a high negative predictive 
value, meaning that when no hrHPV DNA is detected, the risk 
of CIN3 lesions or cervical cancer is low. On the other hand, 
hrHPV DNA can also be detected in transient infections that 
may not persist, and therefore, do not result in cervical cancer.
One outcome of hrHPV infections is viral DNA integration 
into the host genome, which also demonstrates the utility of 
hrHPV DNA testing in screening. Hudelist et al. reported that 
viral integration could be associated with the grade of the 
lesions, while Wei et al. described similar findings and 
Figure 2. Viral biomarkers during HPV infection and progression to cervical cancer. After HPV infection at the basal membrane in the epithelia (virus 
detectable on DNA level), the virus will replicate its genome at low copy numbers, maintaining a latent infection in the basal keratinocytes. Next, the infection will 
switch to a productive infection where the virus expresses its genome, while keratinocytes differentiate, forming koilocytotic cells (E4+) and finally resulting in the 
release of the virus in the upper layers of the epithelia, enabling viral load assessment. After viral release, virions can re-infect the basal membrane leading to 
a persistent infection. Persistent infections present a higher risk of undergoing HPV genome integration to the host genome in the epithelia, resulting in cervical 
intraepithelial neoplasia (CIN) and the progression of these lesions cause cervical cancer. Nevertheless, the lesions can also regress thanks to the response of the host 
immune system that generates infection clearance. Approximately, in 70% of the cases, hrHPV16 and 18 genotypes are the causative agents of the progression to 
cervical cancer, which makes viral genotyping an essential biomarker. Besides, the progression of HPV infection to cervical cancer is highly related to the viral 
oncoproteins E4 and E6/E7; therefore, the analysis of their protein and transcriptional levels, respectively, is important as a biomarker testing for the disease. This 
infection progression is also associated with the HPV DNA methylation patterns that are higher in later stages of the lesions and cervical cancer.
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recommended to include the testing of hrHPV integration in 
hrHPV DNA-based screening programs [42,43]. Since hrHPV 
DNA integration is not required for cervical dysplasia, this 
viral process may not be a good predictor of disease. 
However, hrHPV DNA itself can be detected in both infection 
outcomes, showing its utility in disease progression Figure 2.
The first application of hrHPV DNA testing was for triage of 
ASCUS cytology since the precancer risk of HPV-positive 
ASCUS is the same as LSIL [40]. The ASCUS-LSIL Triage Study 
(ALTS) determined that repeated cytology after an ASCUS 
result referred more women to colposcopy in comparison 
with hrHPV DNA testing [44]. The study also explained that 
this strategy required two visits to cytology to achieve similar 
sensitivity to viral DNA testing (95.4%). Therefore, hrHPV DNA 
testing represents a practical approach for managing women 
with initial ASCUS cytology [44,45]. Nowadays, there is a lot of 
evidence suggesting that this test offers a significant improve-
ment over the more traditional Pap cytology screening due to 
its ability to detect more precancerous disease and higher 
reproducibility [46]. Based on this scientific evidence and cost- 
effectiveness, hrHPV DNA testing has been proposed to 
replace cytology in primary screening programs [32,47]. In 
fact, in some countries, like Turkey, Italy, or The Netherlands, 
hrHPV DNA testing is the first-line initial screening program 
[32–34,48]. Women are free to choose between going to the 
general practitioner (GP), who will take a smear, or use a self- 
sampling kit that is sent by regular mail. Cytology is performed 
on hrHPV-positive GP-collected samples. Those positive 
women with cytological abnormalities are referred to colpo-
scopy, while those with normal cytology will have to be 
followed-up [32].
Regarding the performance of the hrHPV DNA testing on 
regular cytology versus self-sampling, it has been observed 
that hrHPV positivity was higher in clinician-collected samples 
than in self-collected samples (9.2% vs. 7.6%). However, 
among hrHPV-positive women, more women had 
a cytological abnormality after self-sampling than after clini-
cian-collected sampling (37.2% vs. 32.2%) [32]. The same study 
claims that self-sampling has a higher CIN2+ specificity than 
the clinician-collected test. In other studies, it was noted that 
genotypes different than HPV16/18 were more often found in 
self-sampling material [25,32,48]. Similarly, results from 
a meta-analysis (2018) show that PCR-based hrHPV assay is 
sensitive for the detection of CIN2/3+ but slightly less specific 
on self-samples compared with clinician-collected samples.
The assays based on signal amplification, like Hybrid 
Capture II (HC2) and Cervista, have lower sensitivity to detect 
CIN2/3+ and less specificity to exclude CIN2+ on self-samples. 
On the other hand, when mRNA testing like APTIMA was used, 
self-sampling was less sensitive but equally specific as clini-
cian-collected samples. Further studies have compared the 
accuracy of self-samples with clinician samples using specific 
sampling devices or storage media, and the accuracy does not 
vary substantially across clinical settings [49].
One novel hrHPV DNA assay is careHPV. The use of this test 
demonstrates not only the utility of the biomarker but the 
wide range of benefits that lower-cost testing can provide to 
women, particularly in developing countries [49,50]. It has 
a cost around $5 per test, and it is able to detect a pool of 
14 hrHPV genotypes in three hours. The method used for this 
testing does not require specialized training and education, 
and importantly, it possesses high sensitivity and specificity 
towards precancerous and cancerous lesions [50]. The test can 
be performed with both clinician-collected samples and self- 
collected samples. Furthermore, after the implementation of 
careHPV as primary screening in China, Zhao et al. showed 
that the assay has the best cost-effectiveness performance and 
the highest benefit-cost ratio in comparison to HC2, and Pap 
cytology [51,52].
The main advantage of implementing the primary hrHPV 
DNA screening into the nationwide program is a higher detec-
tion of CIN2+ lesions. However, at the same time, more colpo-
scopy referrals per screening round are needed in order to 
detect one CIN2+ lesion compared with cytology-based test-
ing [32]. Further research also confirmed the usefulness of this 
biomarker, even after CIN treatment. In a systematic review 
and meta-analysis by Kocken et al.the authors described that 
hrHPV DNA testing had a higher sensitivity than cytology six 
months post-treatment in women with CIN2+, without redu-
cing its specificity [53]. Thus, hrHPV DNA testing could also be 
included in the follow-up of treated women to detect post- 
treatment lesions. Still, additional triage tests are required to 
distinguish hrHPV DNA positive women with high risk for 
cervical disease from women with transient infections, which 
could reduce overdiagnosis, unnecessary referrals, and follow- 
ups, and therefore, should be a priority [40].
2.2. hrHPV genotyping
Although the prevalence of specific hrHPV types varies geo-
graphically, several epidemiological studies have shown that 
the most frequent genotype in invasive cervical cancer is 
HPV16, followed by HPV18, with both accounting 70% of all 
cases [10,40,41,54] Figure 2. HPV45 is rarely found in women 
with normal cytology or low-grade lesions compared to 
HPV16, but it is the third most common HPV genotype in 
invasive cervical cancer [55]. Vinokurova et al. reported that 
HPV16, 18, and 45 are more likely to be integrated into the 
host cell genome than other HPV genotypes, triggering chro-
mosomal instability that will lead to earlier tumorigenesis by 
activating cellular oncogenes or inactivating cellular tumor- 
suppressive genes. Thus, these genotypes are associated 
with an elevated risk of cervical cancer [54].
There is an increasing interest in using the hrHPV genotyp-
ing test as an additional biomarker to better predict the risk 
for cervical cancer, in part because this method is also applic-
able for self-sampling material. A study using self-sampling 
with dry collection medium (FTA elute micro card), instead 
of a liquid medium, have shown that HPV genotypes found in 
these samples are almost identical to the ones present in the 
samples collected by physicians. Some viral genotypes are 
only positive in self-samples, as the vagina carries HPV geno-
types that are not present in the endocervix [56]. Moreover, 
the American Society for Colposcopy and Cervical Pathology 
proposes that positive hrHPV women with normal cytopatho-
logical test should undergo HPV genotyping analysis, instead 
of waiting to be rescreened after one year. This will make it 
possible to triage women with a low risk of progressing to 
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CIN3/cancer from those with a higher risk [10]. Additionally, 
Ebisch et al. suggested that the combination of HPV16/18 
genotyping with cytology testing may improve the referral 
rate and specificity for detecting CIN3+ lesions, maintaining 
the sensitivity during triage [57].
The ATHENA study is one of the largest clinical trials to 
assess the performance of the HPV genotyping test. They 
showed that the proportion of women positive for the 14 
hrHPV genotypes are seen to rise with increasing CIN grade 
across all age groups [58]. In addition, the Kaiser Permanente 
Northern Carolina and NHANES study showed that the pre-
valence of 14 hrHPV genotypes, including HPV16 and 18, may 
vary according to the age groups. Their prevalence increases 
in the age group of 14–24 years old and might have a non-
significant gradual decline in the age group of 25 years old 
and older [58–60]. HPV genotyping based on the detection of 
HPV16, HPV18, or a pooled detection of 12 more hrHPV types 
(31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) in cervical scrapes 
reached a sensitivity of 90.0%, specificity of 70.5%, PPV of 
14.0% and NPV of 99.2% according to ATHENA study. If 
a woman is positive for HPV16 or 18, immediate referral to 
colposcopy is suggested, whereas positivity for other HPV 
genotypes leads to cytology referral. Therefore, a negative 
result provides the safety that CIN3+ lesions will not develop 
in the next three years [58].
Overall, this viral biomarker may be useful to triage women 
after a positive primary screening (hrHPV DNA testing, cytol-
ogy). Therefore, this marker can potentially be used to stratify 
women with a higher risk to develop CIN3+ lesions and pro-
gression to cervical cancer. hrHPV genotyping may also sup-
port the categorization of women with ASCUS/LSIL/CIN1, who 
have a risk of progression to precancerous lesions because 
hrHPVs tend to progress these lesions to malignancy. 
However, further research is needed to confirm its utility in 
abnormal low-grade lesions, and its value with other indica-
tors, which may enhance its performance for cervical cancer 
screening.
2.3. Viral load
In the HPV life cycle, viral load reflects DNA replication, and 
the levels define the course of hrHPV infection [61]. Several 
studies reported that high HPV viral load (defined as the 
number of HPV DNA copies per cell) is associated with persis-
tent infection and linked to increased risk of cervical intrae-
pithelial neoplasia (CIN) and cervical cancer. In particular, 
HPV16/18 DNA positive women with high DNA load are 
more likely to progress to high-grade CIN Figure 2 [61–64]. 
Halec et al. showed that 93% of high load hrHPV infections 
present in smears are also HPV DNA and mRNA positive in 
their corresponding tissues, representing active infections [65]. 
Based on this information, the viral load could be used as 
a triage tool for HSIL+ in hrHPV16, 18, and 58 positives, to 
determine the group of HSIL+ patients who require treatment 
[62]. Furthermore, increased hrHPV viral load may also lead to 
immune suppression in the microenvironment and result in 
therapy resistance, affecting the survival of patients. Therefore, 
although the viral load has lower levels during early infection, 
the progression to persistent infection, and cervical cancer 
may result in an increment of the viral load, which associates 
with high-grade lesions and malignancy [66,67]. In contrast, 
among patients with ASCUS diagnosis, the viral load might 
not be able to predict their progression to CIN [68].
Viral load during infection and disease progression can vary 
within hrHPV genotypes, which might be a limitation for this 
marker. Initially, Carcopino et al. found that in women referred 
to colposcopy, hrHPV16 viral load had a specificity of 91.0%, 
and a sensitivity of 58.2% for CIN2+ lesions (cut off: 3.0 × 106 
copies per million cells); in comparison, they reported that 
hrHPV18 has a poor predictive value [69]. Nevertheless, 
Schmitt et al. recently determined that detection of multiple 
viral loads from different hrHPV genotypes at the same time 
might be a good predictor of precancerous lesions, including 
ASCUS, but it is not able to distinguish LSIL from HSIL [70]. 
Another limitation is the heterogeneity of the samples. If low- 
grade lesions surround high-grade lesions, cervical scraping 
might result in heterogeneous cytology samples with 
a variable fraction of abnormal cells [71]. Therefore, this 
might have a direct effect on viral load assessment. On the 
other hand, heterogeneity of cytological samples can be cor-
rected by calculating the viral integration status, which could 
be done by the quantitative viral load assessment of type- 
specific HPV E2 and E6 and by defining the ration of the 
integrated load to the total load [62].
While in cervical cancer, higher viral loads are associated 
with a higher risk of progression, in HPV-related oropharyn-
geal cancer, this relation is more variable. Some studies 
reported strong links between high HPV viral loads and better 
survival in HPV related oropharyngeal cancer, anal cancer, and 
vaginal SCC [65]. In contrast, other studies found that HPV 
copy-number is associated with an increased risk of cervical 
abnormality, but that a single viral load does not predict the 
risk of CIN. Besides, it must be noted that viral replication is 
not necessary for maintaining the malignant phenotype as not 
all HPV copies are transcriptionally active [63].
Thus, testing for a single HPV viral load might not be 
relevant for estimating the outcome of hrHPV infections, par-
ticularly for LSIL and NILM. However, taking serial samples, 
detecting multiple hrHPV genotypes viral loads, or combining 
hrHPV viral load with additional biomarkers such as hrHPV 
transcriptional status may be useful for evaluating disease 
progression [63]. Depending on the approach, this marker 
may be able to detect both LSIL and HSIL, supporting the 
triage of women with a positive primary screening. Further 
studies and meta-analyses should clarify these limitations and 
evaluate its specificity and sensitivity towards the different 
stages of disease in order to consider it for screening pro-
grams. Still, the viral load remains an attractive candidate, 
mainly because of its application with additional indicators 
and the ability to use it on self-samples [64].
2.4. hrHPV transcriptional status
In addition to hrHPV DNA testing, which only gives informa-
tion about the virus presence, a significant interest is focused 
on the use of viral mRNA as a biomarker, particularly the 
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upregulation of E6/E7 oncoproteins, to further understand the 
infection state [10,72].
As mentioned, persistent HPV infections are associated with 
a higher risk of integration of the viral DNA into the host 
genome. Indeed, frequent viral integration seems to increase 
with CIN severity [54]. hrHPV integration leads to the disrup-
tion of the E2 gene, which results in the upregulation of E6 
and E7 oncogenes. Additionally, integration of the HPV 
genome causes the generation of fusional viral–cellular tran-
scripts with higher stability, resulting in further increased 
expression of E6 and E7 [73]. The increased levels of E6 and 
E7 proteins interfere with host cell factors such as p53 and 
pRb that control the cell cycle and apoptosis Figure 3. This 
provides a proliferation advantage to infected epithelial cells, 
promoting chromosomal instability that finally results in can-
cer development [54].
Figure 3. Downstream cellular effects of hrHPV E6/7 upregulation. Once expressed, viral E7 interferes with the pRb pathway by binding it and, hence, provoking 
the release of the E2F transcription factor. E2F will translocate to the nucleus where it will transcribe different proliferation-promoting genes; among these: MCM2 
and TOP2A are overexpressed. The E7-pRb binding will avoid the negative feedback loop essential for the p16INK4A regulating protein (p16), which will be 
overexpressed to compensate for the following high proliferation level. At the same time, E6 binds p53 by promoting its degradation, which will cause the release of 
the Sp1 transcription factor, and also the impairment of p53-mediated interference with the pRb pathway. In fact, p53 prevents the phosphorylation of pRb; thus, 
the consequent activation of E2F. This event leads to the inhibition of apoptosis and transcription of Sp1-associated genes, like DNA methyltransferase enzymes 
(DNMTs) that will enhance the methylation of various promoters associated with HPV-mediated processes. The combination of these changes will provoke the 
boosted proliferation of the cell, which will be a signal for the production of Ki-67, a nuclear protein. In addition, E6 will upregulate the expression of TERT and TERC, 
essential for repairing telomeres. Soon, the cell could gain the chromosomal regions containing these two elements (3q and 5p), leading to genomic instability. It is 
believed that these events will facilitate viral genome integration, resulting in transforming cells. The abnormally over-expressed molecules involved in this process 
represent useful cellular biomarkers. TERC: telomerase RNA component; TERT: telomerase reverse transcriptase gene; MCM2: minichromosome maintenance protein 
2; TOP2A: topoisomerase II alpha; CDK4/6: cyclin-dependent kinase 4 and 6.
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Since E6/E7 overexpression is correlated with neoplastic 
features, the transcriptional status of these oncogenes is an 
excellent predictive marker for progression from HPV infection 
to high-grade CIN [74,75]. It has been observed that E6/E7 
mRNA positivity is higher in women with high-grade lesion 
than with low-grade lesion or without lesion and that both E6/ 
E7 mRNA levels and severity of the cervical disease increase 
together [76,77]. Consequently, E6/E7 negativity is higher in 
women that do not have any lesion, which could mean that 
the virus stays in an episomal state or that the regulation of its 
transcription is still controlled, allowing a spontaneous clear-
ance of the infection [75] Figure 2.
Several studies have compared the performance of E6/E7 
mRNA-based assays with hrHPV DNA testing, and they all 
concluded that E6/E7 mRNA testing had higher specificity 
and PPV for HSIL and invasive squamous cell carcinoma 
(ISCC), compared to hrHPV DNA testing [78–81]. 
Furthermore, Fontecha et al. claim that the mRNA test com-
bined with cytology has more clinical relevance than hrHPV 
DNA screening in women with low-grade lesions [75]. 
Similarly, in a recent meta-analysis by Macedo et al.it was 
reported that E6/E7 mRNA has a sensitivity of 93.9% and 
a specificity of 61.7% for CIN2+ lesions [82].
The effectiveness of U.S. FDA approved hrHPV E6/7 mRNA 
assay (APTIMA) was evaluated by Stoler et al.who concluded 
that among women with ASCUS cytology, detection of hrHPV 
E6/E7 oncogenic mRNA is a significant triage method for 
colposcopy referral. This means that fewer women will be 
exposed to harmful and invasive procedures and that more 
cost savings in screening programs could be achieved [83]. 
Bruno et al. confirmed that women with ASCUS/LSIL diagnosis 
and E6/E7 mRNA positive results have a higher risk of cervical 
lesions progression, therefore demonstrating the usefulness of 
this test for cervical cancer screening [84]. Similarly, Rijkaart 
et al. showed that hrHPV mRNA testing (PreTect HPV Proofer) 
is also valuable for the detection of hrHPV DNA-positive 
women with normal cytology that present positivity for E6/ 
E7 mRNA, indicating that the virus is oncogenically active 
before detecting abnormalities [85]. They claim that hrHPV- 
DNA positive women with normal cytology, but upregulated 
E6/7, have a higher risk of developing CIN2 + . Therefore, 
hrHPV mRNA testing could early predict the potential of 
oncogene transformation to severe dysplasia, detecting 
those women who need direct colposcopy referral [78,85]. 
This could limit unnecessary follow-ups and over referral of 
patients with transient HPV infections [78,85].
Some studies have demonstrated that hrHPV mRNA testing 
on self-collected samples might have similar sensitivity and 
specificity in detecting HSIL as physician-collected cytology. 
For instance, the negative predictive value (NPV) on HPV self- 
samples (83.3%) seems lower but similar to the clinician-taken 
(88.3%) [30,86]. In comparison, another study reported that 
this collecting method has an acceptable sensitivity and spe-
cificity for the detection of CIN2+, and it considered that self- 
sampling was less sensitive for CIN2+ than physician-collected 
sample given that hrHPV detected was present in the vagina 
and was not associated with CIN2 in the cervix [87]. 
Nonetheless, the E6/E7 mRNA test as a biomarker may have 
some limitations. Discacciati et al. claim that it is not a good 
long-term prognostic marker because HPV DNA positive and 
E6/E7 mRNA negative women could become E6/E7 mRNA 
positive throughout their lives because of oncogenic activa-
tion of the virus, changing the clinical behavior of the lesion. 
Thus, they should still undergo follow-up examinations or 
treatment since their risk of CIN2+ is too high [88].
Overall, hrHPV transcriptional status might be a right can-
didate as a primary or secondary screening for cervical cancer. 
Its sensitivity and specificity towards cervical lesions are as 
high as hrHPV DNA testing. As a population-based screening 
setting, it has proved to decrease the number of cytology 
assessments at the cost of increased colposcopy referral rate 
[35]. In addition, it may also help to triage women with other 
positive primary screening, confirming the need for 
a colposcopy referral. Likewise, the biomarker’s ability to be 
used with self-samples and alongside other markers makes it 
an appealing possible new testing target. However, further 
research is needed to determine its performance after CIN 
treatment and clarify its limitations.
2.5. Viral E4 protein
E4 is the most abundant viral protein and is synthesized in the 
mid-layers of the epithelium for viral replication and virion 
formation, showing the onset of a productive HPV infection 
[89]. In the upper layers of the epithelium, E4 proteins accu-
mulate within the lesion in different amounts, depending on 
the lesion grade. This allows for the identification of sites with 
an active infection in biopsy material [90].
One of the characteristics of productive HPV infections is 
the presence of koilocytotic cells in the mid-layers of the 
squamous epithelium Figure 2 that are visible in Pap smears 
and cervical biopsies. These cells contain an acentric and 
hyperchromatic nucleus relocated by a perinuclear vacuole 
filled with glycogen [7,91]. The onset of E4 expression coin-
cides with the beginning of vacuolation and loss of defined 
nuclear margins that subsequently form koilocytotic cells 
[7,91]. This morphology contributes directly to virus replication 
in the upper epithelial layer while causing keratinocyte fragi-
lity and cytopathic effect, hindering the assembly of the cor-
nified envelope [92]. Therefore, koilocytosis is a negative 
predictor of CIN3+ as it correlates with a low-grade squamous 
intraepithelial lesion (LSIL) and non-progressive CIN1 lesions 
[93,94].
Levels of E4 decrease with the severity of the lesion. E4 is 
highly expressed in CIN1, and low levels of E4 are found in 
CIN3. E4 is, therefore, a potential biomarker of clinically tran-
sient insignificant disease cleared by the immune system 
[7,89]. It is also of value for detecting and monitoring the 
extent and persistence of LSIL and its possible progression to 
higher-grade lesions [90]. Thus, E4, as a biomarker, could 
facilitate the division of the heterogeneous CIN2 patients 
into those who resemble the CIN1 group (E4 positive) and 
those who are more likely to evolve to a CIN3 stage (E4 
negative) [95]. Moreover, the utility of this protein as 
a biomarker has been tested by several studies. One recent 
research used E4 combined with MCM2 (a host proliferation 
marker) to identify insignificant cervical transient infections 
and found that in CIN2+ lesions, MCM2 was highly expressed 
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while E4 was not present. On the contrary, <CIN1 lesions 
showed most cells stained positive for E4 [11]. Similarly, 
Griffin et al. compared the expression of E4 to p16INK4A, 
another host marker, and the hypermethylation of some host- 
cell genes, which increases with CIN severity. They claim that 
E4 expression is correlated with low hypermethylation and the 
absence of p16INK4A, which is not observed in cervical carci-
noma, as described in additional studies [7,96,97].
The described significant expression of E4 during the pro-
gression of hrHPV infections may allow its implementation in 
multiple steps of cervical cancer screening and management. 
E4 testing can act as a triage of women with positive primary 
screening and stratify them into those with a risk to disease 
progression or regression. It may support the follow-up of 
ASCUS/LSIL diagnosis because its detection could serve as an 
indicator of cervical lesion progression. It may also help with 
the follow-up of treated women, determining those who may 
develop therapy resistance. Nevertheless, further studies 
should confirm these functional activities and indicate the 
sensitivity and specificity towards cervical lesions during their 
progression and regression.
2.6. Viral DNA methylation
Epigenetic alterations like DNA methylation are essential 
mechanisms of gene regulation in cell development and 
defense. In addition to changes in methylation of the host 
genome, HPV DNA methylation is being used as a new bio-
marker for cervical cancer screening in hrHPV-infected women. 
DNA methylation is a defense cellular mechanism from the 
host to silence invading foreign viral genomes and to inhibit 
viral replication [98]; therefore, the methylation of HPV DNA 
may be the host response to the infection, but it might also be 
the result of the viral switching from a productive infection to 
neoplastic transformation [99,100]. The detection of these 
epigenetic changes, particularly the early (E) and late (L) pro-
moters of HPV, may be useful as a predictive or diagnostic 
biomarker among HPV-positive women.
The research in viral methylation (m) has been focused on 
different regions of HPV DNA. For instance, one study recently 
concluded that the degree of L1m in hrHPV (16, 18, and 52) 
was associated with the severity of the cervical lesion, but the 
same pattern was not found in HPV58 [98]. Another study by 
Wentzensen et al. observed that the HPV genotypes 31, 18, 
and 45 had hypermethylated regions of E2, L2, and L1 and low 
methylation in E6, E7, and E1, and that there is increased 
methylation at the viral CpG sites in CIN3 [95]. Likewise, 
Kalantari et al. determined that the methylation pattern of 
viral CpG sites within the HPV16 late promoter may increase 
with the grade of lesions. They found that 10% to 12.2% of all 
CpGs were methylated in asymptomatic infection and ASCUS, 
but in LSIL/CIN1 samples, methylated CpGs increased to 
13.6%, while in HSIL/CIN2+ lesions to 31.9%, and in cancer 
to 83.1%. They also reported similar results to HPV18, 31, and 
45, which demonstrate that the methylation pattern of this 
viral region in disease progression may behave alike among 
hrHPV genotypes [101]. Thus, these findings suggest that viral 
DNA methylation patterns might increase with disease pro-
gression. Additionally, an investigation from Brazil studied HPV 
DNA methylation in E1/E2 regions in cervical cancer samples, 
and they found higher methylation with intact E1/E2 for 
HPV16 and 18 [102]. Clark et al. also showed that methylation 
of HPV was associated with 12 genotypes, marking the transi-
tion from hrHPV infection to precancer. This methylation assay 
showed higher sensitivity (80% vs. 76.6%) and lower test 
positivity compared with cytology (38.5% vs. 48.7%) [103].
The use of viral DNA methylation may be beneficial for the 
triage of women. This biomarker might be used to detect 
high-grade lesions, therefore, improving referral to colposcopy 
Figure 2. Although its utility looks promising, the overall 
results suggest that the host cellular epigenetic machinery 
may respond differently to viral genomic regions such as the 
early and late promoters, and hrHPV genotypes. Thus, it is 
necessary to consider these limitations, and evaluate the sen-
sitivity and specificity towards HSIL in future studies and meta- 
analyses before its application in cervical cancer screening and 
management.
3. The cellular biomarkers
Since many years are required for a persistent HPV infection to 
become cervical cancer, eventually, various cellular changes 
occur in the host. These can reflect an abnormal situation, 
indicative of an HPV-related cellular transforming process, 
and serve as host biomarkers. Therefore, to identify reliable 
biomarkers and how they function, the global picture of the 
involved altered molecular pathways should be considered 
[104–106].
3.1. From an HPV-infected to a transforming cell
The expression of HPV oncoproteins, E6 and E7, is the key 
element in the alteration of the cell cycle, compromising 
various host pathways Figure 3. The alteration of such path-
ways, over the years, could exacerbate, leading to the devel-
opment of cervical cancer. As shown in Figure 3, the 
progressive expression of E6/E7 viral proteins compromises 
many cell cycle-associated regulatory processes with time, 
generating the abnormal coexpression of some molecules 
that can be considered cellular biomarkers in HPV-related 
pathological circumstances. Thus, these altered-pathways bio-
markers can be used and combined in different clinical phases 
to track the progression of the pathologic development [2].
3.2. p16INK4A
Located on chromosome 9p21, the p16INK4A gene belongs to 
the CDK inhibitors family. Together with p19ARF, it performs 
an anti-proliferative activity. p16INK4A and p19ARF proteins 
interfere, respectively, with pRb and p53 pathway [105,106]. 
p16INK4A (p16) is a hrHPV specific progression biomarker, and 
its reliability has been broadly studied. In fact, Carozzi et al. 
showed that p16 positive women, who were monitored in the 
follow-up, presented more frequency of CIN2 or worse (8.8%) 
when compared to the p16 negative women (3.7%), especially 
in the age interval 35–60 years. Remarkably, the authors prove 
that p16 positivity combined with HPV positivity is 
a significant marker to distinguish patient who need an 
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immediate colposcopy referral (HPV-positive, p16-positive) 
from those who can avoid immediate colposcopy and can 
be safely managed with repeat screening after 2–3 year inter-
vals (HPV-positive, p16-negative)[107]. In multiple studies, 
a higher number of p16 positive results were associated with 
a higher grade CIN, and a weaker expression of p16 correlated 
to less severe CIN lesions, confirming the role of p16 as 
a progressive biomarker in the cervical disease development 
[39,105,106,108]. In fact, p16 expression associates with the 
trend of cytology grading, an observation reported by Zeng 
et al.who described lower expression in NILM (9.28%), higher 
in ASCUS (33.33%), increased in LSIL (53.37%), and even higher 
in HSIL (95%). Thus, demonstrating its utility in distinguishing 
high-grade cervical lesions [109]. In practice, p16 staining 
could be used ancillary in cervical cytology and histology 
[110–112]. In a population-based screening setting it could 
be performed on an additional slide from the same scrape, 
from which cytology was made, using commercially available 
kit (CINtecPlus, Roche mtm Laboratories, Germany). However 
clear guidelines should be available regarding its use in rou-
tine practice, as a predictive evaluation of the scoring systems 
to reach a consensus on the threshold of positivity is 
unclear [113].
The regulatory role of p16 depends on a negative feedback 
loop given by pRb. In healthy conditions, p16 binds CDK4/6, 
preventing its linking to cyclin D Figure 4. They form 
a complex that would phosphorylate pRb, causing the release 
of E2F, a transcription factor that enhances the G1/S transition 
genes. The CDK4/6/p16 interaction avoids this process, 
leading to cell cycle regulation. However, in an HPV-infected 
cell, E7 competes with E2F for pRb binding, provoking the 
activation of the transcription factor and, hence, the E2F- 
correlated-genes transcription. This mechanism leads to the 
annulation of the pRb-p16 negative feedback loop, bringing to 
an abnormal overexpression of p16, preventing its interaction 
with CDK4/6, and leading to cell cycle re-entry and progres-
sion. This process is driven by the virus to allow neoplasia and 
genome amplification. However, it is important to mention 
that p16 upregulation is not always HPV-driven [105,106]. 
p16 overexpression in non-HPV-related cancers was observed 
in malignant transformation of both pre-malignant lesions as 
well as in malignant tumors [114–116]. While p16 overexpres-
sion in benign lesions is associated with senescence induction 
in response to oncogenic stimuli, its overexpression in malig-
nant tumors is related to Rb-pathway alterations and almost 
always correlates with high Ki67 index [117]. Rb loss is 
a frequent event in many neoplasms and is associated with 
uncontrolled cell proliferation. In this sense, deregulation of 
Rb results in increased p16 expression in tumor cells and 
cancer tissue due to positive feedback [118]. Because of this 
pathway, p16 dysregulation has been correlated to many 
malignancies, including cervical cancer. Eventually, E7 med-
iates the modification of host histone architecture; among 
these, p16 promoter will also be activated, causing an even 
higher expression of the protein [119–121]. On the other hand, 
patients with cervical cancer have less expression of p16 due 
to hypermethylation of its promoter, leading to unsuccessful 
suppression of tumor growth, and therefore allowing cancer 
Figure 4. Mechanism of regulation mediated by p16INK4A during healthy conditions and HPV infection. In healthy non-HPV-infected cells (left), p16INK4A (p16) 
serves as a fundamental regulator of the cell cycle induction. When a cell has to go through G1/S transition, the cyclin-dependent kinases 4 and 6 (CDK4/6) forms 
a complex with cyclin D. The entire complex phosphorylates the retinoblastoma protein (pRb), which, in normal conditions, binds the transcription factor E2F. The 
phosphorylation mediated by the CDK4/6-cyclinD complex provokes E2F release, which promotes the transcription of those essential genes for the G1/S transition 
phase. At the same time, when the same healthy cell has to go towards cell cycle arrest, the regulatory protein p16 forms a complex with CDK4/6, preventing its 
binding to cyclin D and, hence, the transcription of E2F-correlated genes. However, in an HPV-infected cell (right), the viral protein E7 competes for the binding of 
pRb, and their linkage permits the release of E2F and the transcription of G1/S-genes. The expression of p16 will try to regulate the entire process, but the 
transcription factor release does not depend on CDK4/6-cyclinD phosphorylation; instead, it depends on E7 viral activity. Negative feedback mediated by pRb-E2F 
controls the expression of p16; hence, since this complex no longer exists, the loop is disrupted, and this will result in overexpression of p16 even if its regulatory 
activity is not accomplished.
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development [122–124]. The methylation of the p16 promoter 
also seems to increase with the stages of the disease, particu-
larly in CIN1 and CIN2 lesions [122,125,126]. Similarly, the 
presence of some deleterious SNPs may lead to high/medium 
expression of p16 [127]. Thus, even though p16 represents an 
excellent biomarker, such observations should be considered 
as limitations of this marker. Interestingly, specific SNPs in p16 
have been recently associated with either protection or risk to 
cervical cancer lesions, which further increases p16 value in 
screening HSIL [128,129].
The subcellular location of p16 might play a significant role 
in its functional activities. The protein can be found in the 
nucleus and cytoplasm, where it can inhibit CDK4/6 or get 
sequestered by CDK4, AE1, or other proteins, respectively 
[106]. Therefore, although the overexpression of p16 will 
lead to increased inhibition of CDK4/6, it may not be able to 
induce its anti-tumor activity in the cytoplasm after HPV per-
sistent infection and disease progression. This was recently 
described by Mendaza et al.who determined that the absence 
of nuclear p16, as a result of cytoplasmic sequestration, may 
be an indicator of progression from HSIL to cervical cancer, 
and poor outcomes [110]. Thus, further research is needed to 
clarify the subcellular localization of this protein and the 
meaning of these findings in terms of its utility as a tumor 
suppressor and as a biomarker for the disease.
Overall, as a single biomarker of disease, p16 overexpres-
sion may facilitate the triage of women with initial positive 
screening, and its association with HSIL might support prompt 
diagnosis and progression of LSIL. However, it is important to 
consider the downregulation of p16 due to hypermethylation 
of its promoter and the effect of particular SNPs in its half-life. 
Likewise, the absence of nuclear p16 may support differentiat-
ing HSIL from cervical cancer, which might be helpful in 
patients with CIN2+ diagnosed lesions.
3.3. Ki-67 and dual staining
Due to the E6/E7-caused dysregulation in the cell, the abnor-
mal proliferation triggers the expression of Ki-67. The latter is 
a nuclear protein that can be found expressed in all the cell 
cycle phases, excluding G0. In a normal situation, its expres-
sion is limited to the basal and parabasal layers of the cervical 
squamous epithelium but in the HPV-pathological condition, it 
is expressed in more than one-third of the epithelium. Its 
extension and high expression in the epithelium in prolifera-
tive circumstances make Ki-67 an interesting biomarker to 
consider [130,131]. Moreover, the coexistence of Ki-67 and 
p16 is rarely observed in healthy conditions, meaning that, 
when found overexpressed, these two biomarkers indicate an 
HPV-related alteration of the cell cycle. Indeed, the coexpres-
sion of p16/Ki-67, in 138 cervical biopsies, was detected only 
in dysplastic lesions [132,133]. In light of these findings, p16/ 
Ki-67 dual staining has been proposed and validated as 
a triage test after hrHPV positivity [31]. Surprisingly, the p16/ 
Ki-67 dual staining showed a higher sensitivity for CIN3, if 
compared to p16 staining alone [130]. A recent meta-analysis 
demonstrated that p16/Ki-67 staining is more specific for CIN2 
+/CIN3+ than hrHPV DNA testing. The researchers also 
pointed out that, although p16 staining is less sensitive for 
CIN3+ than hrHPV DNA testing, dual staining has similar sen-
sitivity. In addition, the sensitivity of the co-staining in cervical 
samples was higher than the cytology test, presenting 
a similar specificity [134–136].
Remarkably, Ebisch et al. suggested that the hrHPV-based 
screening could benefit from the replacement of the Pap 
cytology test for p16/Ki-67 dual staining, considering the 
reduced role of morphology, the higher specificity for CIN3, 
and the maintained adequate sensitivity. At last, the adding of 
dual-stain cytology following the low-grade Pap cytology test 
can also be considered in the diagnosis strategy [137]. 
Schmidt et al. also reported a similar conclusion, in women 
with initial ASCUS/LSIL cytology and follow-up testing with 
p16/Ki-67 staining, this biomarker showed a sensitivity for 
CIN2+ of 92.2% (ASCUS) and 94.2% (LSIL), while having a spe-
cificity of 80.6% and 68.0%, respectively [112]. Thus, showing 
that this strategy is useful for detecting HSIL, which could 
avoid unnecessary colposcopy and allow a broader timeframe 
of follow-up between hrHPV DNA positive, ASCUS/LSIL cytol-
ogy, and negative triage women [132].
3.4. TOP2A and MCM2
Due to the elevated expression of E6/E7 viral proteins in the 
cell during the oncogenesis process, E7 binding to pRb pro-
motes E2F transcription factor release, which enhances the 
prolonged-expression of G1/S phase genes, among those, 
TOP2A and MCM2. Topoisomerase II alpha (TOP2A) plays 
a vital role in S-phase because of its enzymatic uncoupling 
activity during the DNA replication process. On the other 
hand, minichromosome maintenance protein 2 (MCM2) is 
essential since it loads complexes onto DNA before replication 
and permits the synthesis through its helicase activity 
[108,138]. Both proteins increase in the proliferating cells 
after the aberrant S-phase induced by hrHPV oncoproteins 
E6/E7. Thus, the overexpression of both during aberrant 
S-phase is currently utilized to detect the disease in research 
settings. In addition, both seem to be considerably expressed 
during the transition from CIN2/3 to invasive cervical cancer 
(ICC); in fact, higher levels were detected in more severe 
cervical lesions, suggesting their potential role as progressive 
late biomarkers [131,139]. Furthermore, one recent study from 
Brazil tested the effectiveness of this biomarker with Ki-67, and 
they concluded that TOP2A is very useful to diagnose high- 
grade lesions (HSIL). At the same time, Ki-67 is useful for 
atypical squamous cells of undetermined significance 
(ASCUS) and low-grade lesions (LSIL) [131]. However, further 
validation is needed to confirm this finding.
One of the readily available kits that use the detection of 
TOP2A and MCM2 overexpression is the ProEx™ 
C immunoassay for in vitro diagnostic. The assay works with 
monoclonal antibodies to detect MCM2 and TOP2A proteins in 
abnormal cervical tissue. Dixon et al. concluded that this assay 
showed intense nuclear staining correlated with cervical lesion 
severity [121]. When the performance of BD ProEx™C assay 
was compared to other markers such as p16INK4A, one study 
concluded that these three biomarkers (MCM2, TOP2A, and 
p16) have the same sensitivity and specificity in the detection 
of high degree CIN [108]. Also, when it was compared to 
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hrHPV DNA testing, Hybrid Capture 2 (HC2; Qiagen®), the assay 
demonstrated high specificity but lower sensitivity for CIN2 
+ lesions, a limitation to consider for triage of ASCUS and LSIL 
[140]. Alaghehbandan et al. confirmed this finding, determin-
ing that both ProEx™ C and E6/E7 mRNA testing have higher 
specificity but lower sensitivity than hrHPV DNA testing for the 
detection of CIN2+ in women with initial ASCUS/LSIL cytology 
[141]. Additionally, Ding et al. recently demonstrated that 
women with an initial diagnosis of LSIL by ProEx™ 
C immunostaining have a higher risk of developing HSIL in 
the next two years. They showed that this test might achieve 
a sensitivity of 75.0%, specificity of 64.5%, PPV of 30.8%, and 
NPV of 92.40% in LSIL lesions that may progress to HSIL [142]. 
Therefore, these overall results suggest that TOP2A/MCM2 
biomarkers have excellent performance for both low and high- 
grade lesions.
TOP2A/MCM2 biomarker correlates with hrHPV DNA posi-
tive cells and has high effectiveness in the detection of cervi-
cal lesions. However, its utility should be elucidated with 
further meta-analyses that corroborate its specificity and sen-
sitivity during cervical cancer progression [139,143]. Although 
more research is needed, this biomarker may also be helpful 
to triage women with LSIL before the lesions progress to HSIL 
and to confirm CIN2+ lesions. Furthermore, one new approach 
for the use of MCM2 as a biomarker is the detection of its gene 
in samples. Tang et al.using bioinformatics analysis, concluded 
that the MCM2 gene plays an essential role in cervical cancer, 
and it might represent an important marker for diagno-
sis [144].
3.5. Chromosomal alterations
Cervical cancer is characterized by chromosomal aberrations 
and the integration of the viral DNA to the host genome. The 
ICC-correlated aberrations that have been observed are loss 
regions (2q, 3p, 4p, 5q, 6q, 11q, 13q, and 18q) or gain regions 
(1q, 3q, 5p, 8q) in the chromosomes, which some of them 
been found in precancerous lesions; hence, they can function 
as biomarkers. The most observed chromosomal alteration in 
precancerous stages is a gain of 3q [31]. Overall, it is now 
believed that the global genetic instability coming from HPV- 
induced aberrations would be the cause of HPV-genome inte-
gration into host DNA and not the consequence [145].
Additionally, the expression of the viral oncoproteins, 
among many things, leads to the gain or loss of specific 
chromosomal regions, depending on the advantage of HPV- 
infected cells. Remarkably, evidence has been presented on 
the expression of TERC (telomerase RNA component) and TERT 
(telomerase reverse transcriptase gene) in an HPV-infected 
cell. Both are critical for the process of repairing telomeres 
avoiding cell death, which is useful to obtain the immortaliza-
tion of the cells. Interestingly, both chromosomal regions 
containing those elements have been observed in cervical 
carcinogenesis: 3q for TERC and 5p for TERT. In transforming 
cervical cells, 3q gain represents an advantage since not only 
TERC is contained and widely transcribed in this chromosomal 
region, but also PIK3CA. The latter codifies for the p110a 
catalytic subunit of phosphatidylinositol-3-kinase, an essential 
enzyme regulating apoptosis and cell growth [135,145,146]. 
The gain of 3q26, which is the specific region containing TERC, 
has been directly associated not only with cervical cancer but 
also with its severity grade. 3q gain seems to represent an 
optimal early-stage biomarker due to the generated genomic 
instability anticipating HPV DNA integration [147].
Wright et al. studied the amplification of this region as 
a biomarker. The analysis of 199 samples resulted in 
a sensitivity of 92.9% (95% confidence interval [CI], 76.5–-
98.9%), a specificity of 100% (95% CI, 97.8–100%), a positive 
predictive value (PPV) of 100% (95% CI, 86.7–100%), and 
a negative predictive value (NPV) of 98.8% (95% CI, 95.9–99.8), 
for distinguishing CIN2 and CIN3 from normal epithelia [148]. 
The study demonstrated supporting evidence of this marker in 
the clinical evaluation of hrHPV-infected women. Interestingly, 
Sokolova et al.by studying the genomic instability in epithelial 
cells of cervical cytology samples, determined that the gain of 
3q26 was positive in 100% of cancer samples, 90% of CIN3, 
78% of CIN2, 26% of CIN1, and 0% of normal samples [149]. 
Therefore, demonstrating the progressive state of this chro-
mosomal gain and its utility for CIN2+ lesions. Likewise, 
Heitman et al. showed that this biomarker could be used as 
a negative triage test for LSIL, having a sensitivity and NPV of 
80% (95% CI, 28–99%) and 98% (95% CI, 87–100%), respec-
tively, for 3q26 gain in women with LSIL cytology [150]. In 
contrast, recent research by Koeneman et al.using the FISH 
technique, showed that the absence of 3q26 gain in diagnos-
tic biopsies might be applied to identify high-grade CIN 
lesions with a high probability of disease regression 
[147,150]. 3q26 gain was found in women with persistence 
and regression of high-grade CIN [147]. Still, none of the 
women without a 3q26 increase showed disease persistence. 
They also concluded that a 3q26 increase could be 
a biomarker for the identification of CIN with a high probabil-
ity of disease regression instead of progression to cervical 
cancer. Thus, more studies with a larger sample population 
are imperative for conclusive results about the value of 3q26 
as a biomarker of cervical cancer.
Regarding chromosomal loss of heterozygosity (LOH), the 
most altered chromosomes are 3 and 6. LOH at 3p14.2 and 
6p21.2 have been associated to recurrent cervical dysplasia 
after progression to cervical cancer and recovery post- 
treatment, respectively [151,152]. In addition, Arias-Pulido 
et al. demonstrated that a mutation in the HLA system, 
which increased the development of carcinoma in situ and 
ICC in HPV16 positive patients, was also associated to the 
generation of LOH at chromosome 6. The team further sug-
gested that such chromosomal aberration could be the result 
of viral persistence [153]. Interestingly, LOH at chromosome 6 
has been found as a marker of progression from CIN to 
cervical cancer [154]. Likewise, Chambuso et al. confirmed 
that HPV alone can induce LOH at chromosome 6, but addi-
tionally the researchers observed that women co-infected with 
HIV may intensify this alteration, and therefore have higher 
risk of CIN progression [155].
The chromosomal gain of 3q26 may support the triage of 
women with positive primary screening. This biomarker might 
detect high-grade lesions, determining CIN2+ lesions, and the 
progression of LSIL. However, its use as a marker of regression 
and the variable expression in different age groups are some 
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characteristics of this indicator that need further research 
[156]. Similarly, LOH at chromosome 6 might be a good can-
didate marker for detecting progression of high-grade lesions 
to cervical cancer and for evaluating recurrent cervical lesions 
after treatment. Thus, it is also necessary to evaluate the 
sensitivity and specificity of these chromosomal alterations in 
additional meta-analyses, which may elucidate their utility as 
biomarkers of the disease.
3.6. Host DNA methylation
The methylation of host promoters has been widely studied in 
correlation to many cancer types, given the consequent down-
regulation of some genes involved in negative regulation of 
cell growth that grant advantages to transforming cells. 
Recent studies have demonstrated the association of host 
DNA methylation (m) with cervical neoplasia and cervical can-
cer; therefore, this approach is being increasingly adopted in 
biomarker research [157]. Concerning the global mechanism, 
several reports revealed that the oncoproteins E6/E7 are able 
to induce the overexpression of DNA methyltransferase genes 
as DNMT1, DNMT3A, DNMT3B, allowing them to increase the 
overall methylation pattern when compared to a healthy con-
dition [98,158].
By using massive deep-sequencing approaches, several 
genes have been observed to be methylated throughout the 
transformation from CIN to cervical cancers; among these, 
CADM1, EPB41L3, FAM19A4, MAL, miR-124, PAX1, and SOX1 
have shown to be prominently elevated in high-grade CINs 
[159]. Notably, the methylation of cell adhesion molecule 1 
(CADM1) and T-lymphocyte maturation associated protein 
(MAL) promoters have explicitly been correlated to CIN3. In 
fact, the analysis of their epigenetics pattern could distinguish 
CIN3+ lesions as efficiently as cytology in a triage test 
[135,160].
One Taiwanese hospital-based study, using TaqMan-based 
quantitative methylation-specific polymerase chain reaction 
(QMSP) technique, found that for CIN3+, PAX1m had 64% 
sensitivity and 91% specificity, while SOX1m had 71% sensitiv-
ity and 77% specificity. The research also revealed that hrHPV 
DNA testing had 89% sensitivity and 68% specificity, and Pap 
smear conferred the best performance with 91% sensitivity 
and 90% specificity for CIN3 + . Moreover, combined parallel 
testing of Pap smears and PAX1m level gave better specificity 
(84% vs. 66%; p < 0.0001 by chi-square test) and equivalent 
sensitivity (93% vs. 97%; p = 0.2450 by chi-square test) to the 
combination of Pap smears and hrHPV DNA testing [160]. 
These findings led to the approval by the Taiwanese FDA of 
PAX1 methylation testing as an adjunct to cytology for cervical 
cancer screening in 2016 [98,161].
The pattern of FAM19A4m has been proposed together 
with miR-124-2 m for triage in hrHPV-infected women to ana-
lyze CIN and progression to cervical cancer in a methylation 
profile assay [162,163]. One study by Vink et al. demonstrated 
a positivity rate of over 98% in their evaluation of FAM19A4/ 
miR124-2 methylation analysis in an extensive analysis of cer-
vical cancer [164]. In 2016, Qiagen® launched the QIAsure test 
based on FAM19A4m and miR-124-2 m, which possess a sensi-
tivity of 100% for cervical cancer in women with hrHPV 
positive results [165]. In addition, the combined FAM19A4m 
and miR-124-2 m analysis have been proven to be particularly 
efficient in identifying CIN3+ women in HPV-positive lavage 
and brush self-samples [166]. Hence, it has been proved that 
the methylation pattern increases with CIN grade, showing 
significantly higher methylation of host genes in CIN3 if com-
pared to CIN2 and global methylation in invasive cervical 
cancer. This evidence confirms the possibility of using the 
methylation pattern of certain genes in screening and triage 
tests as a potential progressive biomarker for severe CIN, in 
other words, for late stages lesions [162,167,168]. Regarding 
the performance of host DNA methylation markers in low- 
grade intraepithelial lesions, Bu et al. recently determined 
that FAM19A4m had a positive correlation with the grading 
of cytology. They observed that the methylation rate was 
10.61% for no CIN, 35.48% for LSIL, 56.14% for HSIL, and 
93.44% for cervical cancer [169]. Similarly, Dankai et al. 
reported that when the methylation status of CADM1, 
FAM19A4, and MAL is compared in different lesions, they all 
increase in HSIL. In fact, FAM19A4m was better differentiating 
ASCUS+ from NILM/ASCUS/LSIL, while CADM1 was able to 
distinguish HSIL+ from negative/LSIL [170]. Thus, proving 
that these methylation markers may have a better potential 
for detecting high-grade lesions.
Host DNA methylation is now being considered as a valid 
alternative triage strategy to cytology for hrHPV DNA positive 
women. This is due to its molecular-basis assay, not dependant 
on morphology and subjective interpretation, as well as to its 
proven higher sensitivity for CIN2+ detection. Worthy of note, 
Verlaat et al. studied directly on self-samples an effective methyla-
tion pattern for three gene promoters, specific for the detection of 
CIN3 and ICC in hrHPV DNA positive self-collected samples; these 
genes were ASCL1, LHX8, and ST6GALNAC5 [171]. The methylation 
analysis for these promoters and others can be performed directly 
on the self-sample used to detect hrHPV DNA, facilitating the 
triage test, and avoiding losing women in the follow-up steps 
[171,172].
Furthermore, Hsu et al.after having studied the different 
methylation status for various HPV types, proved that the 
methylation pattern of host genes seems to vary depending 
on the HPV genotype, suggesting that further investigations 
on these differences should follow [98]. The discovery of new 
host DNA methylation genes that could be useful for biomar-
kers of cervical cancer keeps growing through the years. Xu 
et al. found, in their study, increased expression of the genes 
RAB3C, GABRA2, ZNF257, SLC5A8, and the decreased expres-
sion of GABRA2, ZNF257, and SLC5A8. Although they have high 
sensitivity and specificity, further studies are needed to evalu-
ate their clinical significance [157].
In conclusion, host DNA methylation may support the 
triage of women after hrHPV DNA testing and might be 
a good candidate for primary screening. Some instances of 
these methylated genes are FAM19A4, MAL, CADM1, and 
PAX1, which have been widely studied, but further research 
is needed to validate their utility. Nowadays, a combination 
of host promoter methylation patterns is available to be 
coupled to hrHPV genotyping for a solid molecular-base 
triage strategy, assuring a good sensitivity for late-stage 
lesions.
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3.7. MicroRNAs
MicroRNAs (miRNAs) are also alternative biomarkers that are 
involved in the pathogenesis of cervical cancer by posttran-
scriptional regulation of gene expression. They are small RNA 
molecules of 20–23 nucleotides that do not encode proteins 
[173]. Researchers have detected a lot of miRNAs overex-
pressed or with decreased expression in association with dis-
ease, among these, mi-R-9, miR-21, miR-127, mi-R155, miR- 
199a have been discovered to increase, and miR-143, 
miR214, miR-218, miR-125b, miR-375, miR-34a to decrease in 
cervical tumors [31,39]. Specifically, miR-21, miR-27a, miR-34, 
miR-34a, and miR-196a showed to be particularly highly 
expressed in squamous cell carcinoma of the cervix [174]. 
More investigations about miRNAs testing have been done, 
and recent research has confirmed that miR-29a downregula-
tion is correlated to cervical cancer progression. This has been 
described to be valid also for the downregulation of miR-34a, 
miR-125, and miR-375, which seems to be increasingly dysre-
gulated when passing from CIN1 to ICC, suggesting 
a hypothetical role as progression markers [174]. These 
miRNAs are also indicated for testing in larger populations to 
be included in the screening process of the disease. Another 
study, using the sRNA-Seq technique in HPV-positive self-sam-
ples, confirmed their deregulated expression to be associated 
with CIN3 and cervical cancer development and concluded 
that this method could become a novel triage strategy for 
the disease [175].
The evaluation of the utility of miRNAs in low-grade lesions 
is limited. Recent research by Ye et al. determined that miR- 
29a has a sensitivity of 92.6, positive predictive value of 46.2%, 
negative predictive value of 98.3%, and specificity 80.7% for 
detecting missed high-grade lesions in LSIL/CIN1 diagnosed 
patients [176]. Therefore, demonstrating that this biomarker 
may be a good candidate for triage in cervical cancer pro-
grams. Furthermore, Okoye et al. found that when miRNAs are 
analyzed in both serum and cervical samples, they may have 
a better association with malignancy, and therefore, can 
distinguish abnormal cervical lesions. They reported an 
increase of miR-21, miR-146a, miR-155, miR-182, and miR- 
200 c, and a decrease of miR-145 in serum, which were asso-
ciated with cervical lesions [177]. Thus, proving the usefulness 
of miRNAs and proposing a new method for detecting these 
markers in serum samples.
Similarly, the upregulation of three miRNAs, miR-9, miR-21, 
and miR-155, has been relevantly pointed out as diagnostic 
tools. miR-21 is commonly found in many cancers, both from 
solid and leukemic samples. It is one of the most expressed 
miRNAs in mammal tissues, and its expression seems to down-
regulate PDCD4 tumor suppressor [178]. On the other hand, 
miR-9 enhances cell motility promoting an eventual metasta-
sis, while miR-155 supports the proliferation of the cells by 
regulating LKB1 expression [179]. Indeed, miR-21 is associated 
with CIN and cervical cancer. Moreover, Park et al. found that 
the overexpression of miR1-155 was particularly linked to the 
elevated risk of cervical cancer development in HPV E6/E7 
mRNA positive samples [180]. Overall, the upregulation or 
downregulation of some miRNAs appears to be potentially 
reliable biomarkers, even from a progression perspective. 
These markers might be used to triage women after the 
primary screening with hrHPV DNA testing, particularly for 
ASCUS, LSIL, and HSIL cervical lesions. Further studies should 
uncover their exact cellular mechanisms and diagnostic value 
to permit their adoption in prevention tests.
Altogether, these viral and cellular biomarkers (summarized 
in Table 1) have demonstrated being good candidates for 
cervical cancer screening and triage. They can predict the 
outcome of hrHPV infection in either progression to disease 
or regression to normal, and particularly, have shown to 
increase specificity and sensitivity towards HSIL and specific 
cervical intraepithelial lesions (CIN) Figure 5. Therefore, their 
use within the screening programs might improve the diag-
nosis of precancerous stages of the disease. In combination 
with self-sampling, they could become essential diagnostic 
tools in low- and middle-income countries, which should be 
studied in further research.
Table 1. Existing and candidate biomarkers for cervical cancer screening and triage.
Classification Biomarkers Testing methods Application Sensitivity Specificity Status References
Viral hrHPV DNA NA amplification Primary screening 94.3%* 51.3%* IVD, FDA 
approved
[32,48,58,82,181–184]
hrHPV genotyping NA amplification Primary screening, 
triage
90.0%* 70.5%* IVD, FDA 
approved
[10,54,57–60,185]
Viral load NA amplification Triage 91.0%a 58.2%a Research [61–65,68]
hrHPV transcriptional 
status
TMA, NASBA Primary screening, 
triage
93.9%* 61.7%* IVD, FDA 
approvedc
[35,76–83,85,186]
Viral E4 protein Immunostaining Triage N/A N/A Research [7,11,89,90,95]
Viral DNA methylation NGS Triage 80.0%b 65.6%b Research [95,98,102,103]
Cellular p16/Ki-67 Immunostaining Primary screening, 
triage
86.0%* 66.0%* IVD, FDA 
approvedd
[105,106,108,111,132,133,136,187]
TOP2A/MCM2 Immunostaining Triage 73.9%a 77.6%a IVD, Research [7,11,39,108,121,131,139,141]
3q chromosomal gain FISH Triage 72.1%a 90.0%a Research [147,148,156,188]
Host DNA methylation NGS, PCR Primary screening, 
triage
70.5%* 74.7%* IVD, FDA 
approvedc,e
[98,160–162,164–168,171,172]
miRNAs Microarray, qRT- 
PCR
Triage 81.0%* 86.0%* Research [174,175,180,189]
*For the detection of CIN2+ lesions, results from a meta-analysis. aFor the detection of CIN2+ lesions, results for a single study. bFor the detection of CIN3+ lesions, 
results for a single study. cImplemented for use in Europe. dOnly p16 biomarker is U.S FDA approved in the CINtec Histology test by Roche®. eTaiwanese FDA 
approved. NA: nucleic acid; TMA: transcription mediated amplification; NASBA: nucleic acid sequencing-based amplification; NGS: next-generation sequencing; 
FISH: fluorescence in situ hybridization; PCR: polymerase chain reaction; qRT-PCR: quantitative real time-polymerase chain reaction. FDA: Food and Drug 
Administration; IVD: for in vitro diagnostic; N/A: not available. 
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4. Conclusion
hrHPV infections can either progress to disease or regress to 
normal, and conventional methods such as cytology and the 
novel hrHPV DNA testing are unable to distinguish these 
changes. In addition, profiling the risk of cervical cancer 
means a prompt diagnosis, where hrHPV-infected women are 
identified with an infection or low-risk lesions in the cervix. 
The disease has become concentrated in low and middle- 
income countries, where diagnostic and preventive measures 
are limited. Therefore, the attempt to predict the progression 
of hrHPV infection has driven the search and discovery for new 
testing methods that allow the distinction of disease before it 
advances to malignancy. In the past decades, biomarkers have 
been studied and validated as indicators of hrHPV infection 
and the development of cancer. Although their implementa-
tion in the diagnosis flowchart worldwide seems delayed, 
some countries are taking the first steps in the use of these 
significant testing markers.
Existing biomarkers with potential for cervical cancer triage 
and screening include viral markers such as hrHPV genotyp-
ing, load, transcriptional status, E4 protein, and HPV methyla-
tion, and additional cellular markers such as p16/Ki-67, TOP2A/ 
MCM2, chromosomal gains, miRNAs, and host methylation. All 
of them hold a great promise: hrHPV genotyping could help in 
stratifying the risk of women with abnormal low-grade lesions 
(ASCUS/LSIL) and manage the clinical decision, as it is known 
that the risk of disease progression is genotype-dependent; 
E6/E7 mRNA correlates with high-grade lesions, and E4 detec-
tion protein might be used to categorize CIN2+ lesions; the 
p16/Ki-67 dual staining and miRNAs are also remarkably asso-
ciated with high-grade cervical lesions. Additionally, methyla-
tion patterns have been observed in both viral and cellular 
DNA, and they are highly linked to the generation of precan-
cerous lesions and cervical cancer. In general, the evaluation 
of these biomarkers suggests that they exhibit a strong corre-
lation with infection, specific cervical intraepithelial lesions, 
progression to disease, or regression to normal. Thus, these 
biomarkers may be useful in different stages of cervical cancer 
screening and management. For instance, hrHPV genotyping, 
transcriptional status, p16/Ki-67 immunostaining, and quanti-
fication of host DNA methylation seem to be useful markers 
for primary screening of the disease; on the other hand, viral/ 
host DNA methylation, miRNAs, 3q26 chromosomal gain, viral 
load, E4 protein, and TOP2A/MCM2 may have a noteworthy 
performance in the triage of women after primary screening. 
Further research and meta-analyses are needed to have more 
conclusive results about these observations and their limita-
tions, with additional analysis that clarify their utility in 
patients diagnosed with abnormal cytology such as ASCUS 
Figure 5. Viral and cellular biomarkers for detecting specific stages of cervical intraepithelial lesions after a hrHPV infection. After hrHPV infection, the 
cervical epithelia infected starts to proliferate, finally getting transformed to cervical intraepithelial neoplasia (CIN) 1, 2, and 3. Then from CIN3, it progresses to 
cervical cancer. According to our review, several viral and cellular biomarkers may be useful for detecting different stages of CIN. hrHPV-DNA primary test is the best 
test so far to apply in population-based screening. Then in CIN1, besides the hrHPV DNA testing we can also use genotyping; for CIN2: TOP2A/MCM2, p16/Ki-67 
staining, 3q gain in the chromosome, Viral load, hrHPV transcriptional status (E6/E7 mRNA), and E4 protein, with the latter being able to stratify the heterogenous 
CIN2 group in safe lesions (E4 positive) and clinically significant lesions (E4 negative); and for CIN3: Host DNA methylation(m), miRNAs, hrHPV genotyping, and Viral 
DNA methylation (m).
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and LSIL. Similarly, novel approaches for biomarkers discovery 
include the use of proteomics analysis and the study of the 
vaginal microbiome. Further viral and cellular proteins might 
be excellent candidate indicators of disease, e.g., HPV L1 
protein, Claudin-1, VCP, and E-cadherin, which have promising 
results in research [190–194]. Alternatively, the vaginal micro-
biome might be used to dist inguish progression vs. regression 
of disease [195–197]. The overall results from exist ing and 
candidate biomarkers evidence their utility in profiling the 
risk for disease. Therefore, they should be considered for 
research, further validations, and future applications in screen-
ing programs.
Preventing cervical cancer by the t imely detection of 
hrHPV infections and lesions through biomarkers testing is 
very effective, but not enough. There is also a need for 
increasing the involvement of women in screening programs, 
part icularly in developing countr ies. The use of self-sampling 
may be the solution to this problem. It can provide comfort, 
pr ivacy, and an easy-of-use technique to hard-to-reach 
women, which may increase their participation in the pro-
grams. However, incorrect collection of samples may result in 
low sensitivity and specificity for test ing. Therefore, a robust 
and straightforw ard collection method is needed for further 
application strategies. The consideration of this collection 
method also requires the validation of biomarkers under 
these conditions. Consequently, the combination of biomar-
kers test ing and self-sampling for detecting hrHPV infections 
might assist the diagnosis and prevention of the disease, and 
thus, increment the engagement of women to the programs. 
One instance of this strategy is the test careHPV (Qiagen®), 
which is based on the analysis of hrHPV DNA and self- 
sampling for the detection of hrHPV-infected women in low - 
resource settings [49–52].
The recent progress of the Next Generation Sequencing 
(NGS) field will revolutionize the molecular diagnosis of virus- 
related tumors like cervical cancer. Population-based screen-
ing programs need to move towards a more personalized 
approach, and NGS is driving this change by enabling gene 
expression profi ling, detection of epigenetic changes as well 
as a wide range of molecular analyses. So far, NGS and 
‘omics’ studies have had a significant impact on our under-
standing of the etiology of HPV-driven cancers. The integra-
tion of all these new insights into clinical practice w ill 
ultimately lead to better choices of potential biomarkers 
and more effective personalized treatment options, having 
a positive impact on both screening programs and the 
healthcare systems worldwide. It will give clinicians the 
needed support in decision making during diagnosis, and 
their application will result in better cost-effectiveness of 
health policies for cervical cancer prevention and the well- 
being of women.
5. Expert opinion
The implementation of biomarkers for cervical cancer screening 
may improve the timely diagnosis of the disease and detect it 
during an early stage when the high-risk Human papilloma-
viruses (hrHPVs) have only been able to generate a productive 
infection and have developed cervical intraepithelial (CIN) 
lesions. The results of recent research have demonstrated that 
viral and cellular biomarkers such as hrHPV genotyping, hrHPV 
transcriptional status, p16/Ki-67 dual staining, and host DNA 
methylation can be useful in clinical practice, but further 
research is needed to confirm these findings. Despite the fact 
that low-resource settings have also implemented screening 
and prevention methods, their high prevalence of the disease 
exhibits the limited application and reduced involvement of 
women in the programs. Therefore, these particular regions 
need simpler, easier, and high-quality methods to improve 
their current strategies. New collecting methods, such as the 
use of self-samples, seem to be a helpful tool in improving the 
diagnosis rate of the disease. Advances in biomarkers research 
are still needed due to lack of homogeneity in their discovery 
and validation, affecting study designs and the production of 
high standard meta-analyses. Therefore, in order to develop 
these new screening methods, we should focus on investigating 
the promising biomarkers based on standardized guidelines 
that allow easy validations and reproducibility of results, which 
may lead to the innovation of the current diagnosis flowchart of 
the disease and higher cost-effectiveness of the screening pro-
grams. A ground-breaking biomarker is the one that is able to 
detect specifically progression or regression of CIN lesions and 
possess high specificity and sensitivity for stages of the disease. 
Thus, it must detect hrHPV infections and low-grade intraepithe-
lial lesions (LSIL) before they progress to high-grade intraepithe-
lial lesions (HSIL), and from this to malignancy. The future in this 
research field depends on finding these biomarkers, confirming 
and validating their results, and implementing them in screen-
ing programs. Additional biomarkers based on proteomics ana-
lyses and the study of the vaginal microbiome represent 
promising areas for further studies. Eventually, biomarkers may 
be applied into the screening programs worldwide, as it is 
happening in Europe, and together with the use of self- 
sampling, they would facilitate taking clinical management deci-
sions on time, avoiding patient anxiety, over referral to colpo-
scopy, and unnecessary treatments in women, especially in 
developing countries.
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